title: Practice guidelines for lipid-based amphotericin B in stem cell transplant recipients.
abstract: OBJECTIVE
  To provide clinicians who practice in the stem cell transplantation (SCT) setting with practical guidelines for the use of lipid-based amphotericin B (AmB) formulations in SCT patients who have documented or probable invasive fungal infections, are experiencing neutropenic fever, or require secondary prophylaxis for fungal infections.
  
  
  METHODS
  Recommendations are based on the results of a two-day consensus meeting that convened clinicians versed in the management of infectious complications in patients undergoing SCT. This meeting, which was held October 21-23, 1998, in Orlando, Florida, was sponsored by an educational grant from The Liposome Company. In addition, primary articles were identified by MEDLINE search (1980-December 1999) and through secondary sources.
  
  
  METHODS
  All of the articles identified from the data sources were evaluated, and all information deemed relevant was included in this review.
  
  
  RESULTS
  Immunocompromised patients, particularly patients undergoing high-dose chemotherapy with SCT, experience a high degree of morbidity and mortality from invasive fungal infections. Historically, treatment for such infections with conventional AmB had been limited primarily by its associated nephrotoxicity. Lipid-based formulations of AmB have helped to advance the management of invasive fungal infections in the SCT population by offering a treatment alternative that allows for administration of adequate amounts of active drug to produce clinical and mycologic responses, compared with conventional AmB, in a delivery system that is less nephrotoxic. Unfortunately, these agents are relatively expensive. Therefore, patients who are candidates for lipid-based products must be selected carefully.
  
  
  CONCLUSIONS
  Practical guidelines are provided for the use of lipid-based AmB formulations in SCT patients who have documented or probable invasive fungal infections, are experiencing neutropenic fever, or require secondary prophylaxis for fungal infections.
authors.affiliation: Department of Pharmacy, H Lee Moffit Cancer Center, Tampa, FL 33612-9497, USA. quilitz@moffitt.usf.edu
authors.forename: R E
authors.initials: RE
authors.lastname: Quilitz
authors.forename: A D
authors.initials: AD
authors.lastname: Arnold
authors.forename: G R
authors.initials: GR
authors.lastname: Briones
authors.forename: S P
authors.initials: SP
authors.lastname: Dix
authors.forename: C
authors.initials: C
authors.lastname: Ippoliti
authors.forename: L D
authors.initials: LD
authors.lastname: Kennedy
authors.forename: J L
authors.initials: JL
authors.lastname: Lucich
authors.forename: J
authors.initials: J
authors.lastname: Mehta
authors.forename: B G
authors.initials: BG
authors.lastname: Peters
authors.forename: D S
authors.initials: DS
authors.lastname: Tice
mesh_terms: D006801:Humans; D000666:Amphotericin B / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000935:Antifungal Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D004337:Drug Carriers; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D008081:Liposomes; D009181:Mycoses / Q000188:drug therapy / Q000209:etiology / Q000382:microbiology; D016032:Randomized Controlled Trials as Topic
chemical_list: D000666:Amphotericin B; D000935:Antifungal Agents; D004337:Drug Carriers; D008081:Liposomes